A chimeric virus-based probe unambiguously detects live circulating tumor cells with high specificity and sensitivity

Main text

(Molecular Therapy: Methods & Clinical Development 23, 78–86; December 2021)

In the originally published version of this article, the corresponding author did not disclose his financial interest in Tomahawk Oncology Inc., which has licensed an oncolytic herpes simplex virus developed in his lab. The corresponding author regrets this error.